NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

NCT02954471

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Countries: Saudi Arabia

This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through 2015.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Initially diagnosed with breast cancer
* Has a proven result of HER2 testing by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) or any other in situ hybridization (ISH) method
* Alive or not alive

Exclusion Criteria:

\- Inconclusive, equivocal or unavailable result of HER2/neu overexpression by IHC and FISH

Locations (3)

Dammam, Saudi Arabia
Jeddah, Saudi Arabia
Riyadh, Saudi Arabia